ERBB2 and breast carcinoma: It received fast track designation from the FDA in early 2021 based on phase I trial (CTR20171162/ACE-Breast-01) data in HER-2 positive breast cancer, with ORR of 19/29 or 66% (45.7–82.1%) [72].